The Féderation Internationale de Gynécologie et d'Obstétrique (FIGO) and the American Joint Committee on Cancer (AJCC) have designated staging to define carcinoma of the corpus uteri, which applies to uterine sarcoma; the FIGO system is most commonly used.[1,2]
Uterine sarcomas include leiomyosarcomas, endometrial stromal sarcomas, and adenosarcomas.
Table 1. Uterine Sarcomaa
a Adapted from FIGO Committee on Gynecologic Oncology.
b Either G1, G2, or G3 (G = grade).
c Endocervical glandular involvement only should be considered as stage I and no longer as stage II.
d Positive cytology has to be reported separately without changing the stage.
Tumor confined to the corpus uteri.
No or less than half myometrial invasion.
Invasion equal to or more than half of the myometrium.
Tumor invades cervical stroma but does not extend beyond the uterus.c
Local and/or regional spread of the tumor.
Tumor invades the serosa of the corpus uteri and/or adnexae.d
Vaginal and/or parametrial involvement.d
Metastases to pelvic and/or para-aortic lymph nodes.d
Positive pelvic nodes.
Positive para-aortic lymph nodes with or without positive pelvic lymph nodes.
Distant metastases, including intra-abdominal metastases and/or inguinal lymph nodes.
Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105 (2): 103-4, 2009.
Corpus uteri. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 403-18.
In this article
This information is produced and provided by the National
Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National
Institute via the Internet web site at http://
.gov or call 1-800-4-CANCER.
WebMD Public Information from the National Cancer Institute
September 04, 2014
This information is not intended to replace the advice of a doctor.
Healthwise disclaims any liability for the decisions you make based on this